A Phase 2/3 interventional study of mRNA-1273.211 and mRNA-1273 in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 23 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-28.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 5th largest by enrollment, is one of 21 that started in 2021, is one of 4 in phase 2/3, and was the 19th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 21 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 5,161 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
34 studies in COVID-19 by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 5th largest by enrollment of the 22 interventional ones that give a count, is one of 8 that started in 2021, is one of 4 in phase 2/3, and was the 7th registered.
Moderna, Inc.’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
Among Moderna, Inc.’s 34 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This is a study to evaluate the immunogenicity, safety, and reactogenicity of mRNA-1273.211, mRNA-1273, mRNA-1273.617.2, mRNA-1273.213, mRNA-1273.529, mRNA-1273.214, mRNA-1273.222, mRNA-1273.815, and mRNA-1273.231 administered as booster doses.
This clinical study will consist of 9 parts: A (1 and 2), B, C, D, E, F, G, H, and J.
Part A.1 will evaluate 2 dose levels of the mRNA-1273.211 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part A.2 will evaluate the immunogenicity, safety, and reactogenicity of the mRNA-1273.214 vaccine candidate when administered as a second booster dose to adult participants of the mRNA-1273-P205 study who have previously received 2 doses of mRNA-1273 as a primary series and a first booster of (50 μg total mRNA content) of the mRNA-1273.211 in Part A.1 of this study.
Part B will evaluate the mRNA-1273 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part C will evaluate 2 dose levels of the mRNA-1273.617.2 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part D will evaluate 2 dose levels of the mRNA-1273.213 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part E will be enrolled at a single clinical study site. Part E will evaluate the mRNA-1273.213 vaccine when administered as a single booster dose to adult participants who have previously received 2 doses of any SARS-CoV-2 mRNA authorized vaccine, including mRNA-1273.
Part F will consist of 2 cohorts: Cohort 1 will consist of adults who have previously received 2 doses of mRNA-1273 as primary series. Cohort 1 will evaluate the mRNA-1273.529 vaccine as a single booster dose. Cohort 2 will consist of adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273 in study mRNA-1273-P301 (COVE [NCT04470427]) or under the emergency use authorization (EUA). Cohort 2 will evaluate the mRNA-1273.529 and mRNA-1273 vaccines as a single booster dose.
Part G will evaluate the mRNA1273.214 vaccine candidate when administered as a second booster dose to adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273.
Part H will evaluate the immunogenicity, safety, and reactogenicity of the mRNA- 1273.222 vaccine candidate when administered as a second booster dose to adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273.
Part J will evaluate mRNA-1273.815 and mRNA-1273.231 when administered as a booster dose to adults who previously received a primary series of mRNA vaccine, a first booster dose of a monovalent mRNA vaccine, and a second booster dose of a bivalent mRNA vaccine against SARS-COV-2.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 5,161 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 1 intramuscular booster dose of 50 micrograms (μg) of mRNA-1273.211 on Day 1.
Biological: mRNA-1273.211
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211 on Day 1.
Biological: mRNA-1273.211
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.
Biological: mRNA-1273
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.
Biological: mRNA-1273.617.2
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.
Biological: mRNA-1273.617.2
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213 on Day 1.
Biological: mRNA-1273.213
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
Biological: mRNA-1273.213
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213 on Day 1.
Biological: mRNA-1273.213
Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529 on Day 1.
Biological: mRNA-1273.529
Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.529 or mRNA-1273 enrolled sequentially (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
Biological: mRNA-1273 · Biological: mRNA-1273.529
Participants will receive 1 intramuscular second booster dose of mRNA-1273.214 50 μg on Day 1.
Biological: mRNA-1273.214
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.214 on Day 1.
Biological: mRNA-1273.214
Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.222 on Day 1.
Biological: mRNA-1273.222
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.815 or 50 ug of mRNA-1273.231 on Day 1.
Biological: mRNA-1273.815 · Biological: mRNA-1273.231
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Sterile liquid for injection
Number of Participants With Solicited Local and Systemic ARs
Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an adverse event (AE). A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: 7 days post-vaccination
Number of Participants With Unsolicited AEs
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.
Time frame: Up to 28 days post-vaccination
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study or Treatment Discontinuation
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (EOS) are reported in this outcome measure.
Time frame: Day 1 to EOS (Day 366 for Parts A.1, B, C, D, E, and F; and Day 181 for Parts A.2, H, and J)
Geometric Mean Titer (GMT) of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral severe acute respiratory syndrome coronavirus (SARS-CoV-2) (D614G) at Day 29 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 arbitrary units (AU)/milliliter (mL) and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 181
Seroresponse Rate (SRR) (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 29 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on Pre-vaccination Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 181
SRR (Based on Pre-booster Baseline) For Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant and Ancestral SARS-CoV-2 at Day 181 - mRNA-1273.214 (50 μg) (Part A.2) Compared to mRNA-1273.211 (50 μg) (Part A.1)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 181
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) at Day 29 is reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 29
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 29
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 29
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 91 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 91
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 29
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 29
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 91
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Day 91
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.4/BA.5 Variant and Ancestral SARS-CoV-2 (D614G) at Day 29 - mRNA-1273.222 (Part H) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
GMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the lower limit of detection (LOD) are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 15
GMT of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 29
Geometric Mean Fold Rise (GMFR) of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 15
GMFR of Serum Pseudovirus nAb ID50 Titers Against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5
Time frame: Day 29
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 15
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 15
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 29
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 29
GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 29
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Days 29, 91, 181, and 366
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Days 29, 91, 181, and 366
GMT of Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)
GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 181
GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 181
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 181
SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 181
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
Time frame: Day 181
SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Day 181
SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Days 181 and 366
SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
Time frame: Days 181 and 366
GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) and Ancestral SARS-CoV-2 (D614G) on Days 181 and 366 - mRNA-1273.214 (Part G) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273)
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) on Days 181 and 366 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
Time frame: Days 181 and 366
| Milestone | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 300 | 593 | 0 | 305 | 581 | 586 | 327 | 583 | 42 | 133 | 0 | 0 | 0 | 0 | 0 | 0 |
| Safety set | 300 | 593 | 0 | 305 | 581 | 586 | 327 | 583 | 42 | 133 | 0 | 0 | 0 | 0 | 0 | 0 |
| Solicited safety set | 298 | 591 | 0 | 303 | 577 | 583 | 327 | 583 | 42 | 133 | 0 | 0 | 0 | 0 | 0 | 0 |
| Per-protocol immunogenicity sars-cov-2 negative set (ppis-neg) | 295 | 563 | 0 | 245 | 489 | 547 | 250 | 509 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Per-protocol immunogenicity set (ppis) | 299 | 576 | 0 | 257 | 537 | 569 | 314 | 543 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 276 | 545 | 0 | 267 | 515 | 536 | 291 | 524 | 38 | 110 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 24 | 48 | 0 | 38 | 66 | 50 | 36 | 59 | 4 | 23 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 8 | 20 | 0 | 11 | 43 | 30 | 28 | 23 | 4 | 15 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 3 | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 4 | 0 | 3 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 8 | 23 | 0 | 19 | 20 | 15 | 6 | 24 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Other than specified | 1 | 1 | 0 | 1 | 2 | 3 | 2 | 6 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 135 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 376 | 375 | 437 | 510 | 0 | 0 |
| Safety set | 0 | 0 | 135 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 376 | 375 | 437 | 510 | 0 | 0 |
| Solicited safety set | 0 | 0 | 128 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 350 | 372 | 437 | 507 | 0 | 0 |
| Ppis-neg | 0 | 0 | 76 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 258 | 273 | 334 | 209 | 0 | 0 |
| Ppis | 0 | 0 | 126 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 362 | 358 | 428 | 494 | 0 | 0 |
| Completed | 0 | 0 | 128 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 356 | 345 | 405 | 482 | 0 | 0 |
| Not completed | 0 | 0 | 7 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 20 | 30 | 32 | 28 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 2 | 2 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 10 | 13 | 16 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 16 | 13 | 9 | 0 | 0 |
| Withdrew: Other than specified | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 4 | 0 | 0 | 0 |
| Milestone | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 50 |
| Safety set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 50 |
| Solicited safety set | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 50 |
| Ppis-neg | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 11 | 16 |
| Ppis | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49 | 49 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 50 | 48 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included: injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. All solicited ARs considered causally related to injection were graded 0-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicates lower severity, and a higher score indicates greater severity. The Investigator reviewed whether the solicited AR was also to be recorded as an adverse event (AE). A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Any | 270 | 554 | 113 | 290 | 532 | 548 | 307 | 550 | 41 | 113 | 300 | 323 | 380 | 443 | 44 | 38 |
| Grade 1 | 140 | 215 | 70 | 95 | 260 | 193 | 134 | 213 | 11 | 59 | 184 | 203 | 220 | 219 | 28 | 23 |
| Grade 2 | 98 | 250 | 27 | 144 | 201 | 248 | 127 | 227 | 25 | 43 | 88 | 93 | 125 | 165 | 10 | 14 |
| Grade 3 | 32 | 88 | 16 | 51 | 71 | 107 | 46 | 110 | 5 | 11 | 28 | 27 | 35 | 59 | 6 | 1 |
| Grade 4 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result (hematology, clinical chemistry, or prothrombin time \[PT\]/partial thromboplastin time \[PTT\]) or other safety assessment (for example, electrocardiogram, radiological scan, vital sign measurement), including one that worsened from baseline and was considered clinically significant in the medical and scientific judgment of the Investigator was recorded as an AE. Number of participants with unsolicited AEs (SAEs and non-serious AEs) up to 28 days post-vaccination are reported in this outcome measure.
| Participants | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited AEs | 62 | 126 | 24 | 54 | 134 | 126 | 91 | 135 | 5 | 27 | 80 | 82 | 83 | 119 | 9 | 5 |
An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs included thrombocytopenia, new onset of or worsening of the protocol specified neurologic diseases, anaphylaxis, and myocarditis/pericarditis. An MAAE is an AE that lead to an unscheduled visit to a healthcare practitioner. This included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and/or coronavirus disease 2019 \[COVID-19\] and visits to healthcare practitioners external to the study site (for example, urgent care, primary care physician). Number of participants with SAEs, AESIs, MAAEs, and AEs leading to discontinuation up to the end of study (EOS) are reported in this outcome measure.
| Participants | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SAEs | 6 | 26 | 3 | 15 | 27 | 12 | 8 | 18 | 0 | 2 | 20 | 16 | 23 | 12 | 3 | 2 |
| AESIs | 3 | 16 | 1 | 14 | 24 | 28 | 6 | 25 | 2 | 2 | 10 | 14 | 19 | 9 | 1 | 2 |
| MAAEs | 201 | 388 | 58 | 183 | 380 | 417 | 242 | 401 | 34 | 78 | 279 | 271 | 292 | 253 | 27 | 24 |
| AEs Leading to Discontinuation | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral severe acute respiratory syndrome coronavirus (SARS-CoV-2) (D614G) at Day 29 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5 \* LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 arbitrary units (AU)/milliliter (mL) and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part A.2: mRNA-1273.214 50 μg | Part A.1: mRNA-1273.211 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 4713.5 (3513.5 to 6323.4) | 1897.1 (1433.8 to 2510.1) |
| SARS-CoV-2 (D614G) nAb | 5642.3 (4531.1 to 7025.9) | 2861.4 (2396.0 to 3417.1) |
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 is reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part A.2: mRNA-1273.214 50 μg | Part A.1: mRNA-1273.211 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 2304.6 (1584.4 to 3352.0) | 379.3 (281.0 to 512.1) |
| SARS-CoV-2 (D614G) nAb | 2945.2 (2259.1 to 3839.7) | 1121.4 (927.4 to 1356.1) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part A.2: mRNA-1273.214 50 μg | Part A.1: mRNA-1273.211 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 100 (95.3 to 100.0) | 98.7 (92.9 to 100.0) |
| SARS-CoV-2 (D614G) nAb | 100 (95.3 to 100.0) | 100 (95.3 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part A.2: mRNA-1273.214 50 μg | Part A.1: mRNA-1273.211 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 97.4 (90.8 to 99.7) | 98.7 (92.9 to 100.0) |
| SARS-CoV-2 (D614G) nAb | 93.4 (85.3 to 97.8) | 96.1 (88.9 to 99.2) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part A.2: mRNA-1273.214 50 μg | Part A.1: mRNA-1273.211 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 100 (94.9 to 100.0) | 86.5 (76.5 to 93.3) |
| SARS-CoV-2 (D614G) nAb | 100 (94.9 to 100.0) | 100 (95.1 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 181 are reported. mRNA-1273.214 (50 μg) as a second booster dose (Part A.2) was compared to mRNA-1273.211 (50 μg) as the first booster dose (Part A.1). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part A.2: mRNA-1273.214 50 μg | Part A.1: mRNA-1273.211 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 81.4 (70.3 to 89.7) | 78.4 (67.3 to 87.1) |
| SARS-CoV-2 (D614G) nAb | 71.4 (59.4 to 81.6) | 79.7 (68.8 to 88.2) |
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) at Day 29 is reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| titer | Part F (Cohort 2): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| GMT of Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273 | 2739.5 (2320.2 to 3234.6) | 1462.1 (1260.1 to 1696.4) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part F (Cohort 2): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273 | 99.6 (98.0 to 100.0) | 99.2 (97.2 to 99.9) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. Part F (Cohort 2) mRNA-1273.529 50 μg was compared to Part F (Cohort 2) mRNA-1273 50 μg. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part F (Cohort 2): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273 | 71.4 (65.7 to 76.7) | 53.5 (47.2 to 59.7) |
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 2370.5 (2068.8 to 2716.1) | 1462.1 (1260.1 to 1696.4) |
| SARS-CoV-2 (D614G) nAb | 5971.6 (5316.7 to 6707.2) | 5621.4 (5029.2 to 6283.4) |
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) at Day 91 is reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Omicron BA.1 Variant (B.1.1.529) nAb | 967.3 (835.0 to 1120.6) | 624.2 (533.1 to 730.9) |
| SARS-CoV-2 (D614G) nAb | 3431.5 (3066.7 to 3839.8) | 3447.1 (3054.7 to 3889.9) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 100 (98.9 to 100.0) | 99.2 (97.2 to 99.9) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 29 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 29 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 75.1 (70.2 to 79.7) | 53.5 (47.2 to 59.7) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 98.2 (96.1 to 99.3) | 96.3 (93.0 to 98.3) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Day 91 are reported. mRNA-1273.214 (Part G) was compared the mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Omicron BA.1 Variant (B.1.1.529) at Day 91 - mRNA-1273.214 (Part G) Compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 38.6 (33.3 to 44.1) | 17.7 (13.1 to 23.1) |
GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 is reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part H: mRNA-1273.222 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Omicron Variant (BA.4/BA.5) | 2322.6 (1919.9 to 2809.7) | 483.0 (423.1 to 551.3) |
| SARS-CoV-2 (D614G) nAb | 7328.4 (6390.6 to 8403.8) | 5621.4 (5029.2 to 6283.4) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part H: mRNA-1273.222 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Omicron Variant (BA.4/BA.5) | 98.1 (95.2 to 99.5) | 86.3 (81.5 to 90.3) |
| SARS-CoV-2 (D614G) nAb | 100 (98.3 to 100.0) | 100 (98.6 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 and ancestral SARS-CoV-2 (D614G) at Day 29 are reported. mRNA-1273.222 (Part H) was compared to mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273). Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part H: mRNA-1273.222 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Omicron Variant (BA.4/BA.5) | 91.4 (86.7 to 94.8) | 37.6 (31.7 to 43.8) |
| SARS-CoV-2 (D614G) nAb | 80.9 (74.9 to 86.0) | 43.0 (36.9 to 49.3) |
GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the lower limit of detection (LOD) are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| titer | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SARS-CoV-2 (XBB.1.5) nAb | 1751.2 (1212.5 to 2529.4) | 2579.0 (1809.1 to 3676.7) |
| SARS-CoV-2 (BA.4/BA.5) nAb | 9600.1 (7392.8 to 12466.4) | 9673.4 (6965.6 to 13433.8) |
| SARS-CoV-2 (BQ.1.1) nAb | 1806.7 (1294.1 to 2522.2) | 1894.1 (1383.2 to 2593.6) |
GMT of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| titer | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SARS-CoV-2 (XBB.1.5) nAb | 1985.5 (1388.7 to 2838.8) | 2710.6 (1778.3 to 4131.8) |
| SARS-CoV-2 (BA.4/BA.5) nAb | 10469.7 (7771.5 to 14104.8) | 11231.0 (7883.5 to 15999.9) |
| SARS-CoV-2 (BQ.1.1) nAb | 1727.4 (1293.0 to 2307.6) | 1991.1 (1308.6 to 3029.5) |
GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 15 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| ratio | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SARS-CoV-2 (XBB.1.5) nAb | 11.0 (8.4 to 14.5) | 16.7 (12.8 to 21.7) |
| SARS-CoV-2 (BA.4/BA.5) nAb | 5.0 (3.8 to 6.6) | 6.3 (4.8 to 8.2) |
| SARS-CoV-2 (BQ.1.1) nAb | 5.7 (4.5 to 7.2) | 5.9 (4.8 to 7.4) |
GMFR of serum pseudovirus nAb ID50 titers against SARS-CoV-2 XBB.1.5, BA.4/BA.5, and SARS-CoV-2 BQ.1.1 at Day 29 is reported. GMFR measures the changes in immunogenicity titers or levels from Baseline within participants. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. Antibody values reported as below the LOD are replaced by 0.5 \* LOD. LOD was 10 AU/mL for ID50 titer against XBB.1.5 and BQ.1.1. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5
| ratio | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SARS-CoV-2 (XBB.1.5) nAb | 12.5 (9.6 to 16.3) | 17.5 (13.0 to 23.6) |
| SARS-CoV-2 (BA.4/BA.5) nAb | 5.5 (4.2 to 7.1) | 7.3 (5.4 to 9.9) |
| SARS-CoV-2 (BQ.1.1) nAb | 5.4 (4.3 to 7.0) | 6.2 (4.6 to 8.4) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| percentage of participants | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815 | 100 (88.8 to 100.0) | 100 (90.5 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 15 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| percentage of participants | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 15 - Part J: mRNA-1273.231 and mRNA-1273.815 | 61.2 (46.2 to 74.8) | 69.4 (54.6 to 81.7) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| percentage of participants | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815 | 100 (88.8 to 100.0) | 100 (90.5 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| percentage of participants | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg |
|---|---|---|
| SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 29 - Part J: mRNA-1273.231 and mRNA-1273.815 | 61.2 (46.2 to 74.8) | 67.3 (52.5 to 80.1) |
GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 29 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part F (Cohort 2): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273 | 4951.8 (4349.0 to 5638.0) | 5621.4 (5029.2 to 6283.4) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part F (Cohort 2): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on the Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273 | 100 (98.7 to 100) | 100 (98.6 to 100) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 29 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part F (Cohort 2): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on the Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 29 - Part F (Cohort 2): mRNA-1273.529 and mRNA-1273 | 29.7 (24.3 to 35.5) | 43.0 (36.9 to 49.3) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Day 29 | 100 (98.9 to 100.0) | 100 (98.6 to 100.0) |
| Day 91 | 100 (98.9 to 100.0) | 99.6 (97.7 to 100.0) |
| Day 181 | 99.4 (97.7 to 99.9) | 99.6 (97.7 to 100.0) |
| Day 366 | 97.9 (94.8 to 99.4) | 99.4 (96.9 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) on Days 29, 91, 181, and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Day 29 | 53.9 (48.4 to 59.3) | 43.0 (36.9 to 49.3) |
| Day 91 | 27.4 (22.6 to 32.5) | 18.1 (13.5 to 23.5) |
| Day 181 | 29.5 (24.5 to 35.0) | 19.2 (14.4 to 24.8) |
| Day 366 | 32.6 (26.1 to 39.7) | 27.9 (21.5 to 35.1) |
GMT of serum pseudovirus nAb ID50 titers against BA.4/BA.5 at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| titer | Part H: mRNA-1273.222 50 μg |
|---|---|
| GMT of Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H) | 1424.7 (1123.5 to 1806.7) |
GMT of serum pseudovirus nAb ID50 titers against ancestral SARS-CoV-2 (D614G) at Day 181 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part H: mRNA-1273.222 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| GMT of Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 2906.6 (2465.4 to 3426.9) | 2393.3 (2047.4 to 2797.6) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| percentage of participants | Part H: mRNA-1273.222 50 μg |
|---|---|
| SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H) | 89.9 (84.7 to 93.8) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part H: mRNA-1273.222 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on Pre-vaccination Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 100 (98.1 to 100.0) | 99.6 (97.7 to 100.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against BA.4/BA.5 at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 36.7 AU/mL and ULOQ was 13705 AU/mL for ID50 titer against BA.4/BA.5.
| percentage of participants | Part H: mRNA-1273.222 50 μg |
|---|---|
| SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against BA.4/BA.5 at Day 181 - mRNA-1273.222 (Part H) | 77.2 (70.6 to 83.0) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against ancestral SARS-CoV-2 (D614G) at Day 181 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| percentage of participants | Part H: mRNA-1273.222 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SRR (Based on Pre-booster Baseline) for Serum Pseudovirus nAb ID50 Titers Against Ancestral SARS-CoV-2 (D614G) at Day 181 - mRNA-1273.222 (Part H) and mRNA-1273 (Part F, Cohort 2, 50 μg mRNA-1273) | 45.0 (37.7 to 52.4) | 19.2 (14.4 to 24.8) |
Percentage of participants with seroresponse (based on the pre-vaccination baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Day 181 | 94.5 (91.3 to 96.7) | 90.3 (85.8 to 93.7) |
| Day 366 | 94.8 (90.6 to 97.5) | 89.8 (84.4 to 93.9) |
Percentage of participants with seroresponse (based on the pre-booster baseline) for pseudovirus nAb ID50 against Omicron BA.1 Variant (B.1.1.529) at Days 181 and 366 are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4 \* LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529.
| percentage of participants | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| Day 181 | 40.9 (35.4 to 46.6) | 25.9 (20.5 to 32.0) |
| Day 366 | 52.8 (45.6 to 60.1) | 44.7 (37.3 to 52.3) |
GMT of serum pseudovirus nAb ID50 titers against Omicron BA.1 Variant (B.1.1.529) and ancestral SARS-CoV-2 (D614G) on Days 181 and 366 is reported. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. LLOQ was 19.85 AU/mL and ULOQ was 15502.7 AU/mL for ID50 titer against B.1.1.529. LLOQ was 18.5 AU/mL and ULOQ was 45118 AU/mL for ID50 titer against ancestral SARS-CoV-2.
| titer | Part G: mRNA-1273.214 50 μg | Part F (Cohort 2): mRNA-1273 50 μg |
|---|---|---|
| SARS-CoV-2 (B.1.1.529) nAb: Day 181 | 1044.9 (853.5 to 1279.2) | 693.7 (550.7 to 873.9) |
| SARS-CoV-2 (D614G) nAb: Day 181 | 2683.2 (2300.6 to 3129.5) | 2393.3 (2047.4 to 2797.6) |
| SARS-CoV-2 (B.1.1.529) nAb: Day 366 | 1364.6 (1050.0 to 1773.6) | 1019.7 (776.3 to 1339.4) |
| SARS-CoV-2 (D614G) nAb: Day 366 | 2679.5 (2157.6 to 3327.5) | 2492.3 (2032.3 to 3056.5) |
Collected over Day 1 up to the end of the study (Day 366 for Parts A.1, B, C, D, F, and G; Day 181 for Parts A.2, H, J). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A.1: mRNA-1273.211 50 µg | 1/300 (0.3%) | 6/300 (2%) | 133/300 (44.3%) |
| Part A.1: mRNA-1273.211 100 µg | 0/593 (0%) | 26/593 (4.4%) | 275/593 (46.4%) |
| Part A.2: mRNA-1273.214 50 µg | 0/135 (0%) | 3/135 (2.2%) | 38/135 (28.1%) |
| Part B: mRNA-1273 100 µg | 1/305 (0.3%) | 15/305 (4.9%) | 144/305 (47.2%) |
| Part C: mRNA-1273.617.2 50 µg | 0/581 (0%) | 27/581 (4.6%) | 288/581 (49.6%) |
| Part C: mRNA-1273.617.2 100 µg | 1/586 (0.2%) | 12/586 (2%) | 329/586 (56.1%) |
| Part D: mRNA-1273.213 50 µg | 0/327 (0%) | 8/327 (2.4%) | 188/327 (57.5%) |
| Part D: mRNA-1273.213 100 µg | 0/583 (0%) | 18/583 (3.1%) | 309/583 (53%) |
| Part E: mRNA-1273.213 100 µg | 0/42 (0%) | 0/42 (0%) | 34/42 (81%) |
| Part F (Cohort 1): mRNA-1273.529 50 µg | 0/133 (0%) | 2/133 (1.5%) | 57/133 (42.9%) |
| Part F (Cohort 2): mRNA-1273 50 µg | 2/376 (0.5%) | 20/376 (5.3%) | 193/376 (51.3%) |
| Part F (Cohort 2): mRNA-1273.529 50 µg | 0/375 (0%) | 16/375 (4.3%) | 188/375 (50.1%) |
| Part G: mRNA-1273.214 50 µg | 2/437 (0.5%) | 23/437 (5.3%) | 224/437 (51.3%) |
| Part H: mRNA-1273.222 50 µg | 2/510 (0.4%) | 12/510 (2.4%) | 178/510 (34.9%) |
| Part J: mRNA-1273.231 50 µg | 0/50 (0%) | 3/50 (6%) | 13/50 (26%) |
| Part J: mRNA-1273.815 50 µg | 0/50 (0%) | 2/50 (4%) | 11/50 (22%) |
| Event | Part A.1: mRNA-1273.211 50 µg | Part A.1: mRNA-1273.211 100 µg | Part A.2: mRNA-1273.214 50 µg | Part B: mRNA-1273 100 µg | Part C: mRNA-1273.617.2 50 µg | Part C: mRNA-1273.617.2 100 µg | Part D: mRNA-1273.213 50 µg | Part D: mRNA-1273.213 100 µg | Part E: mRNA-1273.213 100 µg | Part F (Cohort 1): mRNA-1273.529 50 µg | Part F (Cohort 2): mRNA-1273 50 µg | Part F (Cohort 2): mRNA-1273.529 50 µg | Part G: mRNA-1273.214 50 µg | Part H: mRNA-1273.222 50 µg | Part J: mRNA-1273.231 50 µg | Part J: mRNA-1273.815 50 µg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Colonic abscessInfections and infestations | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 0/437 | 0/510 | 1/50 | 0/50 |
| DiverticulitisInfections and infestations | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 0/437 | 0/510 | 1/50 | 0/50 |
| Pelvic inflammatory diseaseInfections and infestations | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 0/437 | 0/510 | 0/50 | 1/50 |
| Tubo-ovarian abscessInfections and infestations | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 0/437 | 0/510 | 0/50 | 1/50 |
| Ventricular tachycardiaCardiac disorders | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 0/437 | 0/510 | 0/50 | 1/50 |
| NephrolithiasisRenal and urinary disorders | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 1/437 | 1/510 | 1/50 | 0/50 |
| FallInjury, poisoning and procedural complications | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 0/376 | 0/375 | 1/437 | 0/510 | 1/50 | 0/50 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/300 | 4/593 | 0/135 | 0/305 | 2/581 | 0/586 | 0/327 | 0/583 | 0/42 | 0/133 | 3/376 | 1/375 | 1/437 | 0/510 | 0/50 | 0/50 |
| Umbilical hernia, obstructiveGastrointestinal disorders | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 1/133 | 0/376 | 0/375 | 0/437 | 0/510 | 0/50 | 0/50 |
| Non-cardiac chest painGeneral disorders | 0/300 | 0/593 | 0/135 | 0/305 | 0/581 | 0/586 | 0/327 | 0/583 | 0/42 | 1/133 | 0/376 | 1/375 | 0/437 | 0/510 | 0/50 | 0/50 |
| Event | Part A.1: mRNA-1273.211 50 µg | Part A.1: mRNA-1273.211 100 µg | Part A.2: mRNA-1273.214 50 µg | Part B: mRNA-1273 100 µg | Part C: mRNA-1273.617.2 50 µg | Part C: mRNA-1273.617.2 100 µg | Part D: mRNA-1273.213 50 µg | Part D: mRNA-1273.213 100 µg | Part E: mRNA-1273.213 100 µg | Part F (Cohort 1): mRNA-1273.529 50 µg | Part F (Cohort 2): mRNA-1273 50 µg | Part F (Cohort 2): mRNA-1273.529 50 µg | Part G: mRNA-1273.214 50 µg | Part H: mRNA-1273.222 50 µg | Part J: mRNA-1273.231 50 µg | Part J: mRNA-1273.815 50 µg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 76/300 | 143/593 | 21/135 | 87/305 | 195/581 | 227/586 | 117/327 | 220/583 | 18/42 | 30/133 | 127/376 | 119/375 | 160/437 | 74/510 | 5/50 | 2/50 |
| Upper respiratory tract infectionInfections and infestations | 27/300 | 63/593 | 6/135 | 21/305 | 49/581 | 49/586 | 38/327 | 53/583 | 15/42 | 9/133 | 33/376 | 31/375 | 36/437 | 36/510 | 4/50 | 2/50 |
| Asymptomatic COVID-19Infections and infestations | 14/300 | 40/593 | 7/135 | 20/305 | 28/581 | 21/586 | 33/327 | 14/583 | 5/42 | 12/133 | 21/376 | 27/375 | 18/437 | 24/510 | 0/50 | 0/50 |
| Rhinovirus infectionInfections and infestations | 14/300 | 19/593 | 4/135 | 9/305 | 22/581 | 36/586 | 11/327 | 25/583 | 3/42 | 5/133 | 18/376 | 11/375 | 27/437 | 25/510 | 3/50 | 5/50 |
| NasopharyngitisInfections and infestations | 0/300 | 1/593 | 0/135 | 16/305 | 2/581 | 8/586 | 0/327 | 4/583 | 4/42 | 0/133 | 2/376 | 0/375 | 0/437 | 6/510 | 0/50 | 0/50 |
| Respiratory disorderRespiratory, thoracic and mediastinal disorders | 0/300 | 0/593 | 0/135 | 1/305 | 1/581 | 1/586 | 0/327 | 0/583 | 4/42 | 0/133 | 0/376 | 3/375 | 3/437 | 1/510 | 0/50 | 0/50 |
| HeadacheNervous system disorders | 6/300 | 24/593 | 3/135 | 6/305 | 27/581 | 32/586 | 10/327 | 24/583 | 1/42 | 12/133 | 9/376 | 15/375 | 11/437 | 21/510 | 2/50 | 1/50 |
| FatigueGeneral disorders | 12/300 | 36/593 | 4/135 | 6/305 | 30/581 | 29/586 | 24/327 | 33/583 | 0/42 | 11/133 | 18/376 | 17/375 | 15/437 | 25/510 | 1/50 | 0/50 |
| BronchitisInfections and infestations | 4/300 | 6/593 | 0/135 | 16/305 | 5/581 | 7/586 | 5/327 | 24/583 | 1/42 | 2/133 | 7/376 | 5/375 | 8/437 | 4/510 | 1/50 | 0/50 |
| HypertensionVascular disorders | 12/300 | 20/593 | 0/135 | 10/305 | 13/581 | 20/586 | 17/327 | 11/583 | 0/42 | 3/133 | 18/376 | 16/375 | 13/437 | 8/510 | 1/50 | 1/50 |
Safety Set included all participants who received IP. Total number of enrolled and treated participants in the study = 5161. All participants of Part A.2 rolled over from Part A.1 and some participants of Parts J rolled over from Part H. Hence, the baseline characteristics data of Part A.2 and Parts J are reported in a separate row.
| Age, Categorical(Participants) | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Parts Excluding Part A.2 and Parts J — <=18 years | 0 | 0 | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — | 0 |
| All Parts Excluding Part A.2 and Parts J — Between 18 and 65 years | 238 | 447 | — | 216 | 466 | 467 | 292 | 426 | 41 | 115 | 226 | 254 | 263 | 405 | — | — | 3856 |
| All Parts Excluding Part A.2 and Parts J — >=65 years | 62 | 146 | — | 89 | 115 | 119 | 35 | 157 | 1 | 18 | 150 | 121 | 174 | 105 | — | — | 1292 |
| Part A.2 and Parts J — <=18 years | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Part A.2 and Parts J — Between 18 and 65 years | — | — | 112 | — | — | — | — | — | — | — | — | — | — | — | 43 | 39 | 194 |
| Part A.2 and Parts J — >=65 years | — | — | 23 | — | — | — | — | — | — | — | — | — | — | — | 7 | 11 | 41 |
| Sex: Female, Male(Participants) | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Parts Excluding Part A.2 and Parts J — Female | 167 | 330 | — | 131 | 313 | 287 | 204 | 284 | 23 | 70 | 190 | 173 | 258 | 316 | — | — | 2746 |
| All Parts Excluding Part A.2 and Parts J — Male | 133 | 263 | — | 174 | 268 | 299 | 123 | 299 | 19 | 63 | 186 | 202 | 179 | 194 | — | — | 2402 |
| Part A.2 and Parts J — Female | — | — | 75 | — | — | — | — | — | — | — | — | — | — | — | 31 | 30 | 136 |
| Part A.2 and Parts J — Male | — | — | 60 | — | — | — | — | — | — | — | — | — | — | — | 19 | 20 | 99 |
| Ethnicity (NIH/OMB)(Participants) | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Parts Excluding Part A.2 and Parts J — Hispanic or Latino | 38 | 51 | — | 66 | 100 | 106 | 32 | 68 | 1 | 17 | 37 | 47 | 46 | 58 | — | — | 667 |
| All Parts Excluding Part A.2 and Parts J — Not Hispanic or Latino | 262 | 538 | — | 237 | 475 | 474 | 294 | 512 | 41 | 113 | 339 | 324 | 390 | 447 | — | — | 4446 |
| All Parts Excluding Part A.2 and Parts J — Unknown or Not Reported | 0 | 4 | — | 2 | 6 | 6 | 1 | 3 | 0 | 3 | 0 | 4 | 1 | 5 | — | — | 35 |
| Part A.2 and Parts J — Hispanic or Latino | — | — | 15 | — | — | — | — | — | — | — | — | — | — | — | 6 | 9 | 30 |
| Part A.2 and Parts J — Not Hispanic or Latino | — | — | 120 | — | — | — | — | — | — | — | — | — | — | — | 43 | 40 | 203 |
| Part A.2 and Parts J — Unknown or Not Reported | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | 1 | 1 | 2 |
| Race (NIH/OMB)(Participants) | Part A.1: mRNA-1273.211 50 μg | Part A.1: mRNA-1273.211 100 μg | Part A.2: mRNA-1273.214 50 μg | Part B: mRNA-1273 100 μg | Part C: mRNA-1273.617.2 50 μg | Part C: mRNA-1273.617.2 100 μg | Part D: mRNA-1273.213 50 μg | Part D: mRNA-1273.213 100 μg | Part E: mRNA-1273.213 100 μg | Part F (Cohort 1): mRNA-1273.529 50 μg | Part F (Cohort 2): mRNA-1273 50 μg | Part F (Cohort 2): mRNA-1273.529 50 μg | Part G: mRNA-1273.214 50 μg | Part H: mRNA-1273.222 50 μg | Part J: mRNA-1273.231 50 μg | Part J: mRNA-1273.815 50 μg | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| All Parts Excluding Part A.2 and Parts J — American Indian or Alaska Native | 1 | 5 | — | 0 | 5 | 1 | 2 | 3 | 0 | 0 | 1 | 3 | 0 | 1 | — | — | 22 |
| All Parts Excluding Part A.2 and Parts J — Asian | 9 | 18 | — | 6 | 23 | 51 | 10 | 26 | 2 | 6 | 16 | 14 | 14 | 11 | — | — | 206 |
| All Parts Excluding Part A.2 and Parts J — Native Hawaiian or Other Pacific Islander | 0 | 1 | — | 0 | 0 | 2 | 1 | 2 | 0 | 0 | 1 | 2 | 0 | 0 | — | — | 9 |
| All Parts Excluding Part A.2 and Parts J — Black or African American | 19 | 34 | — | 17 | 54 | 32 | 23 | 49 | 1 | 26 | 28 | 21 | 31 | 56 | — | — | 391 |
| All Parts Excluding Part A.2 and Parts J — White | 257 | 518 | — | 279 | 473 | 481 | 282 | 478 | 38 | 97 | 322 | 325 | 381 | 425 | — | — | 4356 |
| All Parts Excluding Part A.2 and Parts J — More than one race | 7 | 7 | — | 1 | 7 | 10 | 6 | 12 | 0 | 1 | 2 | 7 | 7 | 8 | — | — | 75 |
| All Parts Excluding Part A.2 and Parts J — Unknown or Not Reported | 7 | 10 | — | 2 | 19 | 9 | 3 | 13 | 1 | 3 | 6 | 3 | 4 | 9 | — | — | 89 |
| Part A.2 and Parts J — American Indian or Alaska Native | — | — | 1 | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 1 |
| Part A.2 and Parts J — Asian | — | — | 1 | — | — | — | — | — | — | — | — | — | — | — | 2 | 1 | 4 |
| Part A.2 and Parts J — Native Hawaiian or Other Pacific Islander | — | — | 0 | — | — | — | — | — | — | — | — | — | — | — | 0 | 0 | 0 |
| Part A.2 and Parts J — Black or African American | — | — | 10 | — | — | — | — | — | — | — | — | — | — | — | 4 | 4 | 18 |
| Part A.2 and Parts J — White | — | — | 117 | — | — | — | — | — | — | — | — | — | — | — | 41 | 45 | 203 |
| Part A.2 and Parts J — More than one race | — | — | 2 | — | — | — | — | — | — | — | — | — | — | — | 2 | 0 | 4 |
| Part A.2 and Parts J — Unknown or Not Reported | — | — | 4 | — | — | — | — | — | — | — | — | — | — | — | 1 | 0 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2021 to primary completion in Nov 2023, 29 months.
Results were first posted in Feb 2025, 1 year 3 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 29 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · mRNA-1273.214 COVID-19 vaccine · Elasomeran/Davesomeran